U.S. officials approved the first pharmaceutical-grade version of the fecal transplant procedures that doctors have increasingly used to treat a potentially life-threatening intestinal infection. kprc2 click2houston fda health
FILE - The Food and Drug Administration building is seen on Dec. 10, 2020, in Silver Spring, Md. U.S. officials on Wednesday, Nov. 30, 2022, have approved the first pharmaceutical-grade version of the so-called fecal transplant procedures that doctors have increasingly used against a hard-to-treat intestinal infections. – U.S.
For more than a decade, some U.S. doctors have used stool samples from healthy donors to treat the condition. The healthy bacteria from donors' gut has been shown to help recipients fight off C. diff bacteria. The procedure has grown more common as many patients no longer respond to traditional antibiotics.
The new therapy from Ferring Pharmaceuticals Inc. is manufactured at a facility in Minnesota from stool donations that are screened for dozens of infections and viruses. The therapy is delivered via the rectum by health professionals as a one-time procedure.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA clears 1st fecal transplant treatment for gut infectionWASHINGTON (AP) — U.S. officials have approved the first pharmaceutical-grade version of the so-called fecal transplant procedures that doctors have increasingly used against hard-to-treat intestinal infections.
Read more »
FDA clears 1st fecal transplant treatment for gut infectionU.S. officials approved the first pharmaceutical-grade version of the fecal transplant procedures that doctors have increasingly used to treat a potentially life-threatening intestinal infection.
Read more »
FDA OKs First Fecal Transplant Therapy for Recurrent C difficileRebyota, a microbiota-based live biotherapeutic prepared from human stool, is intended for use after an individual has completed antibiotic treatment for recurrent C difficile infection.
Read more »
U.S. FDA gives first-ever approval to fecal transplant therapyThe therapy, Rebyota, targets Clostridium difficile, or C. difficile – a superbug responsible for infections that can cause serious and life-threatening diarrhea. In the United States, the infection is associated with 15,000-30,000 deaths annually. While this is the first such therapy approved by the Food and Drug Administration (FDA) for recurrent C. difficile infections, fecal microbiota transplants – classified by the regulator as investigational – have long been the standard of care in the U.S. for this condition.
Read more »
U.S. FDA gives first-ever approval to fecal transplant therapyThe U.S. health regulator on Wednesday approved Switzerland-based Ferring Pharmaceuticals' fecal transplant-based therapy to reduce the recurrence of a bacterial infection, making it the first therapy of its kind to be cleared in the United States.
Read more »
WSJ News Exclusive | Naloxone Startup Pursues FDA Approval for Over-the-Counter SwabA nonprofit that makes an opioid-reversal drug administered with a nasal swab submitted data to the FDA that it said showed better results than spray versions
Read more »